Showing 7601-7610 of 9550 results for "".
- Study Links BMI and IBD Causally to Hidradenitis Suppurativahttps://practicaldermatology.com/news/mendelian-randomization-study-links-bmi-and-ibd-causally-to-hidradenitis-suppurativa/2485068/A new mendelian randomization (MR) analysis provides genetic evidence supporting a causal role for elevated body mass index (BMI) and inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS). Study researchers used gen
- Zasocitinib Phase 3 Data Suggests Potential for Once-Daily Psoriasis Pillhttps://practicaldermatology.com/news/zasocitinib-phase-3-data-sugges-potential-for-once-daily-psoriasis-pill/2484981/Oral TYK2 inhibitor zasocitinib (TAK-279) met all primary and 44 ranked secondary endpoints in two pivotal Phase 3 trials for moderate-to-severe plaque psoriasis, according to a December 18 press release from Takeda. Results f
- Isotretinoin Slows Growth Rate in Teens, But Final Height Unchangedhttps://practicaldermatology.com/news/isotretinoin-slows-growth-rate-in-teens-but-final-height-unchanged/2484962/Adolescents treated with isotretinoin for acne may experience temporary reductions in height velocity, but the medication does not appear to impact final adult height, according to a new retrospective cohort study published in the
- Real-World Study Confirms Ixekizumab Outperforms Ustekinumab in Psoriasishttps://practicaldermatology.com/news/real-world-study-confirms-ixekizumab-outperforms-ustekinumab-in-psoriasis/2484790/A recent real-world studyreplicated the results of the IXORA-S trial, which demonstrated the efficacy of ixekizumab over ustekinumab for treating moderate-to-severe plaque psoriasis. Researchers for the observational analysis, c
- New Series Spotlights Real Stories of MCC Patientshttps://practicaldermatology.com/news/new-series-spotlights-real-stories-of-mcc-patients/2484808/The Skin Cancer Champions Community announced that it will launch its Living With: Merkel Cell Carcinoma (MCC) web series on Wednesday, January 14, 2026, from 12:00 to 1:00pm EST via Zoom. According to a release from the group, the premiere episode,
- Oral Roflumilast Suppresses Psoriatic Inflammation at the Gene and Cellular Level: Studyhttps://practicaldermatology.com/news/oral-roflumilast-suppresses-psoriatic-inflammation-at-the-gene-and-cellular-level/2484789/In a mechanistic substudy of the PSORRO trial, oral roflumilast demonstrated targeted immunomodulatory effects in patients with moderate-to-severe plaque psoriasis. Researchers for the vivo analysis sourght to characterize the dru
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Trial for First Oral Minoxidil for Female Hair Loss Initiates Phase 3https://practicaldermatology.com/news/trial-for-first-oral-minoxidil-for-female-hair-loss-launches-phase-3/2484534/Veradermics, Inc. announced the initiation of patient enrollment in a phase 2/3 registration-directed clinical trial of VDPHL01, a novel extended-release oral minoxidil formulation, according to a press release. If approved, V
- Novartis Launches Head-to-Head Trial of Remibrutinib vs Dupilumabhttps://practicaldermatology.com/news/novartis-launches-head-to-head-trial-of-remibrutinib-vs-dupilumab/2484430/Novartis, manufacturers of remibrutinib (Rhapsido), announced the launch of a US-based phase 3b clinical trial for the evaluation of early efficacy and safety of oral remibrutinib compared to injectable dupilumab in adults with chronic spontaneous urticaria (CSU) in